Tumor Ablation Market Size & Forecast By Technology (Radiofrequency, Microwave, Cryoablation), By Treatment (Surgical, Laparoscopic, Percutaneous) By Application (Liver Cancer, Breast Cancer, Lung Cancer, Prostrate Cancer), And Trend Analysis From 2015 To 2022
Global tumor ablation market is expected to reach USD 1.5 billion by 2022, according to a new study by Grand View Research Inc. Rising prevalence of different forms of cancer and increasing technological advancements in the field of thermal ablation techniques are the most prominent drivers of the market.
Besides the use of thermal ablation, techniques such as laser ablation, irreversible electroporation, High Intensity Focused Ultrasonography (HIFU) are also clinically growing, concurrently propelling the tumor ablation industry.
Occurrence of lung, breast, and liver cancer is on the rise globally. According to the Center for Disease Control (CDC) and other organizations, currently, about 210,828 cases of lung cancer, 2.9 million cases of breast cancer, and over 2.7 million cases of prostate cancer are reported in the U.S. alone.
In terms of technological advancement, companies such as SonaCare Medical are coupling ablation techniques with other technologies to improve accuracy, performance, and level of care. SonaLink, a remote patient monitoring platform, was put to use along with Sonatherm ablation system to enable physicians to enhance patient care experience, thereby promoting market growth.
The industry is also anticipated to witness mergers and joint collaborations as a tool to curb rising competition. For instance, Boston Scientific Corporation acquired C.R. Bard Electrophysiology, which led to a 48.0% hike in profit for the former company.
Further key findings from the study suggest:
Microwave ablation technology is expected to be the fastest growing segment over the forecast period at a CAGR of over 15.0%. Reduction in the procedure time and low cost for treatment are some of the attributes favoring growth.
In terms of treatment, surgical ablation is predicted to form the largest market by 2022 with about 35.0% share. Liver and lung cancer ablation require surgical procedures, and since these form the largest and fastest growing segments, they concomitantly propel surgical ablation growth.
Lung cancer forms the most lucrative market and is anticipated to be the fastest growing segment over the forecast period. By 2022, it is expected to contribute about 15.0% of the revenue share owing to its rising prevalence rate across the globe.
According to market forecast for 2022, North America is expected to dominate the market and Asia Pacific is anticipated to witness the fastest growth. Augmenting growth in the cancer prevalence and rising healthcare expenditure in regions such as China, Korea, and India are factors responsible for this rapid growth.
Major players of the market include HealthTronics, Galil Medical Inc., Angiodynamics, Medtronic Plc. (Covidien), Boston Scientific Corporation, SonaCare Medical, Misonix Inc., EDAP TMS S.A., and Neuwave Medical Inc. To retain market leadership, players such as Medtronic are working towards acquiring other companies and expanding their portfolio. For instance, in January 2016, Medtronic acquired the OsteoCool RF Ablation System from Baylis Medical.
Besides the use of thermal ablation, techniques such as laser ablation, irreversible electroporation, High Intensity Focused Ultrasonography (HIFU) are also clinically growing, concurrently propelling the tumor ablation industry.
Occurrence of lung, breast, and liver cancer is on the rise globally. According to the Center for Disease Control (CDC) and other organizations, currently, about 210,828 cases of lung cancer, 2.9 million cases of breast cancer, and over 2.7 million cases of prostate cancer are reported in the U.S. alone.
In terms of technological advancement, companies such as SonaCare Medical are coupling ablation techniques with other technologies to improve accuracy, performance, and level of care. SonaLink, a remote patient monitoring platform, was put to use along with Sonatherm ablation system to enable physicians to enhance patient care experience, thereby promoting market growth.
The industry is also anticipated to witness mergers and joint collaborations as a tool to curb rising competition. For instance, Boston Scientific Corporation acquired C.R. Bard Electrophysiology, which led to a 48.0% hike in profit for the former company.
Further key findings from the study suggest:
Microwave ablation technology is expected to be the fastest growing segment over the forecast period at a CAGR of over 15.0%. Reduction in the procedure time and low cost for treatment are some of the attributes favoring growth.
In terms of treatment, surgical ablation is predicted to form the largest market by 2022 with about 35.0% share. Liver and lung cancer ablation require surgical procedures, and since these form the largest and fastest growing segments, they concomitantly propel surgical ablation growth.
Lung cancer forms the most lucrative market and is anticipated to be the fastest growing segment over the forecast period. By 2022, it is expected to contribute about 15.0% of the revenue share owing to its rising prevalence rate across the globe.
According to market forecast for 2022, North America is expected to dominate the market and Asia Pacific is anticipated to witness the fastest growth. Augmenting growth in the cancer prevalence and rising healthcare expenditure in regions such as China, Korea, and India are factors responsible for this rapid growth.
Major players of the market include HealthTronics, Galil Medical Inc., Angiodynamics, Medtronic Plc. (Covidien), Boston Scientific Corporation, SonaCare Medical, Misonix Inc., EDAP TMS S.A., and Neuwave Medical Inc. To retain market leadership, players such as Medtronic are working towards acquiring other companies and expanding their portfolio. For instance, in January 2016, Medtronic acquired the OsteoCool RF Ablation System from Baylis Medical.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Tumor Ablation Devices Market– Industry Snapshot and Key Buying Criteria, 2014
CHAPTER 3. TUMOR ABLATION DEVICES INDUSTRY OUTLOOK
3.1. Tumor Ablation Devices Market Segmentation
3.2. Tumor Ablation Devices Market Size and Growth Prospects
3.3. Tumor Ablation Devices Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Industry Analysis - Porter's
3.5. Tumor Ablation Devices Market PESTEL Analysis, 2014
3.6. Competitive Landscape
CHAPTER 4. TUMOR ABLATION DEVICES TECHNOLOGY OUTLOOK
4.1. Tumor Ablation Devices Market Share By Technology, 2014 & 2022
4.2. Radiofrequency Ablation Devices
4.2.1. Radiofrequency Ablation Devices Market Estimates and Forecasts, 2015 – 2022
4.3. Microwave Ablation Devices
4.3.1. Tumor Ablation Devices Market Estimates and Forecasts, 2015 – 2022
4.4. Cryoablation Devices
4.4.1. Cryoablation Devices Market Estimates and Forecasts, 2015 – 2022
4.5. Other Ablation Devices
4.5.1. Other Ablation Devices Market Estimates and Forecasts, 2015 – 2022
CHAPTER 5. TUMOR ABLATION DEVICES TREATMENT OUTLOOK
5.1. Tumor Ablation Devices Market Share By Treatment, 2014 & 2022
5.2. Surgical Ablation
5.2.1. Surgical Ablation Market Estimates and Forecasts, 2015 – 2022
5.3. Laparoscopic Ablation
5.3.1. Laparoscopic Ablation Market Estimates and Forecasts, 2015 – 2022
5.4. Percutaneous Ablation
5.4.1. Percutaneous Ablation Market Estimates and Forecasts, 2015 – 2022
CHAPTER 6. TUMOR ABLATION DEVICES APPLICATION OUTLOOK
6.1. Tumor Ablation Devices Market Share By Application, 2014 & 2022
6.2. Liver Cancer
6.2.1. Liver Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.3. Breast Cancer
6.3.1. Breast Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.4. Lung Cancer
6.4.1. Lung Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.5. Prostrate Metastasis
6.5.1. Prostrate Metastasis Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.6. Other Cancer
6.6.1. Other Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
CHAPTER 7. TUMOR ABLATION DEVICES REGIONAL OUTLOOK
7.1. Tumor Ablation Devices Market Share By Region, 2014 & 2022
7.2. North America
7.2.1. North America Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.2.1.1. U.S. Market Estimates and Forecasts
7.2.1.2. Canada Market Estimates and Forecasts
7.2.2. North America Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.2.2.1. U.S. Market Estimates and Forecasts
7.2.2.2. Canada Market Estimates and Forecasts
7.2.3. North America Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.2.3.1. U.S. Market Estimates and Forecasts
7.2.3.2. Canada Market Estimates and Forecasts
7.3. Europe
7.3.1. Europe Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.3.1.1. Germany Market Estimates and Forecasts
7.3.1.2. UK Market Estimates and Forecasts
7.3.2. Europe Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.3.2.1. Germany Market Estimates and Forecasts
7.3.2.2. UK Market Estimates and Forecasts
7.3.3. Europe Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.3.3.1. Germany Market Estimates and Forecasts
7.3.3.2. UK Market Estimates and Forecasts
7.4. Asia Pacific
7.4.1. Asia Pacific Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.4.1.1. Japan Market Estimates and Forecasts
7.4.1.2. China Market Estimates and Forecasts
7.4.2. Asia Pacific Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.4.2.1. Japan Market Estimates and Forecasts
7.4.2.2. China Market Estimates and Forecasts
7.4.3. Asia Pacific Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.4.3.1. Japan Market Estimates and Forecasts
7.4.3.2. China Market Estimates and Forecasts
7.5. Latin America
7.5.1. Latin America Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.5.1.1. Mexico Estimates and Forecasts
7.5.1.2. Brazil Estimates and Forecasts
7.5.2. Latin America Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.5.2.1. Mexico Estimates and Forecasts
7.5.2.2. Brazil Estimates and Forecasts
7.5.3. Latin America Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.5.3.1. Mexico Estimates and Forecasts
7.5.3.2. Brazil Estimates and Forecasts
7.6. MEA
7.6.1. MEA Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.6.1.1. South Africa Estimates and Forecasts
7.6.1.2. Saudi Arabia Estimates and Forecasts
7.6.2. MEA Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.6.2.1. South Africa Estimates and Forecasts
7.6.2.2. Saudi Arabia Estimates and Forecasts
7.6.3. MEA Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.6.3.1. South Africa Estimates and Forecasts
7.6.3.2. Saudi Arabia Estimates and Forecasts
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Medtronic Plc.
8.1.1. Company Overview
8.1.2. Financial Performance
8.1.3. Product Benchmarking
8.1.4. Strategic Initiatives
8.2. Angiodynamics
8.2.1. Company Overview
8.2.2. Financial Performance
8.2.3. Product Benchmarking
8.2.4. Strategic Initiatives
8.3. Mermaid Medical
8.3.1. Company Overview
8.3.2. Financial Performance
8.3.3. Product Benchmarking
8.3.4. Strategic Initiatives
8.4. HealthTronics
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. Product Benchmarking
8.4.4. Strategic Initiatives
8.5. Galil Medical Inc.
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. Product Benchmarking
8.5.4. Strategic Initiatives
8.6. EDAP TMS S.A.
8.6.1. Company Overview
8.6.2. Financial Performance
8.6.3. Product Benchmarking
8.6.4. Strategic Initiatives
8.7. Boston Scientific Corporation
8.7.1. Company Overview
8.7.2. Financial Performance
8.7.3. Product Benchmarking
8.7.4. Strategic Initiatives
8.8. SonaCare Medical
8.8.1. Company Overview
8.8.2. Financial Performance
8.8.3. Product Benchmarking
8.8.4. Strategic Initiatives
8.9. Misonix, Inc.
8.9.1. Company Overview
8.9.2. Financial Performance
8.9.3. Product Benchmarking
8.9.4. Strategic Initiatives
8.10. Neuwave Medical, Inc.
8.10.1. Company Overview
8.10.2. Financial Performance
8.10.3. Product Benchmarking
8.10.4. Strategic Initiatives
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Tumor Ablation Devices Market– Industry Snapshot and Key Buying Criteria, 2014
CHAPTER 3. TUMOR ABLATION DEVICES INDUSTRY OUTLOOK
3.1. Tumor Ablation Devices Market Segmentation
3.2. Tumor Ablation Devices Market Size and Growth Prospects
3.3. Tumor Ablation Devices Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Industry Analysis - Porter's
3.5. Tumor Ablation Devices Market PESTEL Analysis, 2014
3.6. Competitive Landscape
CHAPTER 4. TUMOR ABLATION DEVICES TECHNOLOGY OUTLOOK
4.1. Tumor Ablation Devices Market Share By Technology, 2014 & 2022
4.2. Radiofrequency Ablation Devices
4.2.1. Radiofrequency Ablation Devices Market Estimates and Forecasts, 2015 – 2022
4.3. Microwave Ablation Devices
4.3.1. Tumor Ablation Devices Market Estimates and Forecasts, 2015 – 2022
4.4. Cryoablation Devices
4.4.1. Cryoablation Devices Market Estimates and Forecasts, 2015 – 2022
4.5. Other Ablation Devices
4.5.1. Other Ablation Devices Market Estimates and Forecasts, 2015 – 2022
CHAPTER 5. TUMOR ABLATION DEVICES TREATMENT OUTLOOK
5.1. Tumor Ablation Devices Market Share By Treatment, 2014 & 2022
5.2. Surgical Ablation
5.2.1. Surgical Ablation Market Estimates and Forecasts, 2015 – 2022
5.3. Laparoscopic Ablation
5.3.1. Laparoscopic Ablation Market Estimates and Forecasts, 2015 – 2022
5.4. Percutaneous Ablation
5.4.1. Percutaneous Ablation Market Estimates and Forecasts, 2015 – 2022
CHAPTER 6. TUMOR ABLATION DEVICES APPLICATION OUTLOOK
6.1. Tumor Ablation Devices Market Share By Application, 2014 & 2022
6.2. Liver Cancer
6.2.1. Liver Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.3. Breast Cancer
6.3.1. Breast Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.4. Lung Cancer
6.4.1. Lung Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.5. Prostrate Metastasis
6.5.1. Prostrate Metastasis Ablation Devices Market Estimates and Forecasts, 2015 – 2022
6.6. Other Cancer
6.6.1. Other Cancer Ablation Devices Market Estimates and Forecasts, 2015 – 2022
CHAPTER 7. TUMOR ABLATION DEVICES REGIONAL OUTLOOK
7.1. Tumor Ablation Devices Market Share By Region, 2014 & 2022
7.2. North America
7.2.1. North America Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.2.1.1. U.S. Market Estimates and Forecasts
7.2.1.2. Canada Market Estimates and Forecasts
7.2.2. North America Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.2.2.1. U.S. Market Estimates and Forecasts
7.2.2.2. Canada Market Estimates and Forecasts
7.2.3. North America Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.2.3.1. U.S. Market Estimates and Forecasts
7.2.3.2. Canada Market Estimates and Forecasts
7.3. Europe
7.3.1. Europe Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.3.1.1. Germany Market Estimates and Forecasts
7.3.1.2. UK Market Estimates and Forecasts
7.3.2. Europe Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.3.2.1. Germany Market Estimates and Forecasts
7.3.2.2. UK Market Estimates and Forecasts
7.3.3. Europe Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.3.3.1. Germany Market Estimates and Forecasts
7.3.3.2. UK Market Estimates and Forecasts
7.4. Asia Pacific
7.4.1. Asia Pacific Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.4.1.1. Japan Market Estimates and Forecasts
7.4.1.2. China Market Estimates and Forecasts
7.4.2. Asia Pacific Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.4.2.1. Japan Market Estimates and Forecasts
7.4.2.2. China Market Estimates and Forecasts
7.4.3. Asia Pacific Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.4.3.1. Japan Market Estimates and Forecasts
7.4.3.2. China Market Estimates and Forecasts
7.5. Latin America
7.5.1. Latin America Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.5.1.1. Mexico Estimates and Forecasts
7.5.1.2. Brazil Estimates and Forecasts
7.5.2. Latin America Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.5.2.1. Mexico Estimates and Forecasts
7.5.2.2. Brazil Estimates and Forecasts
7.5.3. Latin America Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.5.3.1. Mexico Estimates and Forecasts
7.5.3.2. Brazil Estimates and Forecasts
7.6. MEA
7.6.1. MEA Market Estimates and Forecasts, by Technology, 2015 – 2022 (USD Million)
7.6.1.1. South Africa Estimates and Forecasts
7.6.1.2. Saudi Arabia Estimates and Forecasts
7.6.2. MEA Market Estimates and Forecasts, by Treatment, 2015 – 2022 (USD Million)
7.6.2.1. South Africa Estimates and Forecasts
7.6.2.2. Saudi Arabia Estimates and Forecasts
7.6.3. MEA Market Estimates and Forecasts, by Application, 2015 – 2022 (USD Million)
7.6.3.1. South Africa Estimates and Forecasts
7.6.3.2. Saudi Arabia Estimates and Forecasts
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Medtronic Plc.
8.1.1. Company Overview
8.1.2. Financial Performance
8.1.3. Product Benchmarking
8.1.4. Strategic Initiatives
8.2. Angiodynamics
8.2.1. Company Overview
8.2.2. Financial Performance
8.2.3. Product Benchmarking
8.2.4. Strategic Initiatives
8.3. Mermaid Medical
8.3.1. Company Overview
8.3.2. Financial Performance
8.3.3. Product Benchmarking
8.3.4. Strategic Initiatives
8.4. HealthTronics
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. Product Benchmarking
8.4.4. Strategic Initiatives
8.5. Galil Medical Inc.
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. Product Benchmarking
8.5.4. Strategic Initiatives
8.6. EDAP TMS S.A.
8.6.1. Company Overview
8.6.2. Financial Performance
8.6.3. Product Benchmarking
8.6.4. Strategic Initiatives
8.7. Boston Scientific Corporation
8.7.1. Company Overview
8.7.2. Financial Performance
8.7.3. Product Benchmarking
8.7.4. Strategic Initiatives
8.8. SonaCare Medical
8.8.1. Company Overview
8.8.2. Financial Performance
8.8.3. Product Benchmarking
8.8.4. Strategic Initiatives
8.9. Misonix, Inc.
8.9.1. Company Overview
8.9.2. Financial Performance
8.9.3. Product Benchmarking
8.9.4. Strategic Initiatives
8.10. Neuwave Medical, Inc.
8.10.1. Company Overview
8.10.2. Financial Performance
8.10.3. Product Benchmarking
8.10.4. Strategic Initiatives
